First-year progress in MD Anderson’s Moon Shots Program
The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers. Elizabeth Grimm, Ph.D., interim director and chief scientific officer for MD Anderson’s Moon Shots Program, discusses progress since the effort launched one year ago.
Guest: Elizabeth Grimm, Ph.D.
Resources - Moon Shots Annual Report 2013
UT MD cancer moon shots take flight during Year 1
Acute Myeloid Leukemia and Myelodysplastic Syndrome Moon Shot
Breast and Ovarian Moon Shot
Chronic Lymphocytic Leukemia Moon Shot
Lung Moon Shot
Melanoma Moon Shot
Prostate Moon Shot
A year of progress for our Moon Shots Program
UT MD Anderson Cancer Center launches unprecedented Moon Shots Program to increase patient survival during the next decade